Clinical Trial Search

Primary: Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8 — -9.71; -11.28; -11.67 Units on a scale — p=0.006

Primary: Participants With Plasma HIV RNA < 200 Copies/mL 48 Weeks After Randomization — 219; 223 participants

Primary: Mean Bone Mineral Density Changes From Baseline to 48 Weeks as Measured by DXA Scan — -5.2; -2.9 percentage change

Primary: Percentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS) — 11.74 percentage of participants

Primary: Rey Auditory Verbal Learning Test (RAVLT) — 44.8; 44.1 words

Primary: Change From Baseline in Height at Year 1 — 103.6; 103.5; 9.8; 8.6 centimeter

Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 79; 79; 64.7 percentage of participants

Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 72.9; 63.3; 78.0; 55.0 percentage of participants

Primary: Number of Participants With Regular Menstrual Cycles — 192; 9; 3; 199 Participants

Primary: Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0 — 0.40; 0.76; 2.00 Scores on a Scale

Primary: Percentage of Responders as Per Clinical Global Impression - Improvement (CGI-I) Scale — 21.6 percentage of participants

Primary: Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL) — 13; 2 participants

Primary: Modified Fatigue Impact Scale (MFIS) — 12.92; 12.69 units on a scale — p=0.81

Primary: Mean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline — 20.0; -3.8 millimeters mercury (mmHg)

Primary: Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D — 21.9357; 15.5334; 10.7767; 9.1754 µg/mL